Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AG-120 in Healthy Japanese and Caucasian Males
NCT03071770Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML) and cholangiocarcinoma (CCA), sponsored by Agios Pharmaceuticals. Primary endpoints: Area Under the Curve at 21 days and Maximum Plasma Concentration at 21 days. Started Mar 2017; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03071770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071770.